|会社名||Evofem Biosciences Inc （ネオセティクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 Evofem Biosciences Inc formerly Neothetics Inc. is a clinical-stage specialty pharmaceutical company which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is an injectable formulation of the long-acting Beta2-adrenergic receptor agonist and salmeterol xinafoate which is an active ingredient in the United States Food and Drug Administration inhaled products such as SEREVENT DISKUS ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate LIPO-102 an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos or protrusion of the eye from the orbit associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye. ネオセティクスは、米国の製薬会社。審美的な市場のための治療法の開発に従事。局所的な脂肪の減少と体の輪郭に焦点をあて製品の研究開発を行う。非肥満患者の皮下脂肪による中央腹部隆起の縮小のため臨床向けの治療法を開発し、臨床段階の医薬品として、LIPO-202およびLIPO-102を提供する。 Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.|
|本社所在地||12400 High Bluff Drive Suite 600 San Diego CA 92130 USA|
|代表者氏名||Saundra Pelletier Saundra Pelletier|
|代表者役職名||Chief Executive Officer|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Evofem Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $13.6M to $92.4M. Higher net loss reflects Loss on issuance of Invesco Warrants increase from $0K to $47.9M (expense) Research and development increase of 97% to $12M (expense) General and administrative increase of 73% to $9M (expense).|
Why Evofem Biosciences Shares Are Plunging Today? 2022/10/12 18:17:25 Benzinga
Evofem Biosciences Inc''s (OTC: EVFM ) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its endpoints. CEO Saundra Pelletier, trial investigator Brandi Howard and study statistician Clint Dart all blamed the loss on COVID-19''s impact on infection rates … Full story available on Benzinga.com
Stifel Downgrades Evofem Biosciences Inc to Hold 2022/10/12 17:39:02 Investing.com
Evofem''s Phexxi fails in phase 3 trial to prevent chlamydia, gonorrhea in women 2022/10/12 09:55:36 Seeking Alpha
Evofem Biosciences (EVFM) said a phase 3 trial of EVO100 (vaginal gel Phexxi) to prevent chlamydia and gonorrhea infection in women did not achieve its goals and that the company will…
Evofem Biosciences, Inc. (EVFM: OTCQB) | OTC Markets Group Welcomes New OTCQB Companies – October 10 2022/10/10 11:00:00 OTC Markets
Evofem Biosciences Says Vaginal Contraceptive Gel Phexxi Approved In Nigeria 2022/10/06 13:11:59 RTT News
Evofem Biosciences, Inc. (EVFM) announced Thursday that its hormone-free contraceptive vaginal gel Phexxi has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). This is the first regulatory approval outside the U.S.
Evofem (EVFM) And The Phexxi Launch 2022/09/12 15:08:08 Seeking Alpha
An excessive rate of spending has put Evofem in a terrible financial position. Phexxi is a product with a suboptimal profile, and sales figures support this conclusion. Read more here.
Evofem Biosciences Inc PT Lowered to $0.55 at Morgan Stanley 2022/09/09 06:59:11 Investing.com
Pleasing stocks: Akebia Therapeutics, Inc. (NASDAQ:AKBA -3.27%), Evofem Biosciences, Inc. (NASDAQ:EVFM -2.72%) 2022/08/31 03:42:19 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Pleasing stocks: Akebia Therapeutics, Inc. (NASDAQ:AKBA -3.27%), Evofem Biosciences, Inc. (NASDAQ:EVFM -2.72%) appeared first on Stocks Equity .
This stocks will Fire Up Your investment: Evofem Biosciences, Inc. (NASDAQ:EVFM 7.35%), Denison Mines Corp. (AMEX:DNN 16.36%) 2022/08/25 01:25:55 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post This stocks will Fire Up Your investment: Evofem Biosciences, Inc. (NASDAQ:EVFM 7.35%), Denison Mines Corp. (AMEX:DNN 16.36%) appeared first on Stocks Equity .
Overwhelming stocks: Evofem Biosciences, Inc. (NASDAQ:EVFM -5.94%), Tantech Holdings Ltd (NASDAQ:TANH -7.13%) 2022/08/22 00:51:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Overwhelming stocks: Evofem Biosciences, Inc. (NASDAQ:EVFM -5.94%), Tantech Holdings Ltd (NASDAQ:TANH -7.13%) appeared first on Stocks Equity .
EVFM Stock Heats Up Following ''Huge Win.'' 7 Things to Know. 2022/01/12 20:05:33 InvestorPlace
Today, investors in women''s health company Evofem Biosciences and EVFM stock are dancing, following revised birth control regulations.
Evofem scores a “huge win” with revised birth control guidelines - Stifel 2022/01/12 18:00:39 Seeking Alpha
Evofem Biosciences <
> has gained over a tenth after the company highlighted the impact on its birth control gel Phexxi post new federal guidance requiring the payors to…
Why Are Evofem Biosciences Shares Rising On Wednesday? 2022/01/12 15:18:27 Benzinga
Evofem Biosciences Inc (NASDAQ: EVFM ) shares are trading higher after the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor issued updated guidance related to contraceptive access. The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for FDA-approved contraceptive products, like Phexxi, prescribed by healthcare providers. "We Full story available on Benzinga.com
Evofem gains amid prospects for its contraceptive gel under new govt. guidance 2022/01/12 14:01:40 Seeking Alpha
Micro-cap stock Evofem Biosciences (EVFM) has gained ~30.0% on above-average volume after the company highlighted how a newly issued guidance from the U.S
Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs? 2022/01/12 13:35:00 Benzinga
NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com
関連キーワード （医薬品 米国株 ネオセティクス EVFM Evofem Biosciences Inc.）